Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 5, 2024

Genentech

RRID:SCR_003997
Type: Tool

Proper Citation

Genentech (RRID:SCR_003997)

Resource Information

URL: http://www.gene.com/

Proper Citation: Genentech (RRID:SCR_003997)

Description: A biotechnology corporation that uses human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions.

Abbreviations: Genentech

Synonyms: Genentech Inc, F. Hoffmann-La Roche Ltd / Genentech

Resource Type: commercial organization

Keywords: drug, genetic, medicine, biotechnology, oncology, immunology, tissue growth, tissue repair, neuroscience, infectious disease, microbiology, medical imaging

Related Condition: Infectious disease, Cancer

Resource Name: Genentech

Resource ID: SCR_003997

Alternate IDs: nlx_158417

Ratings and Alerts

No rating or validation information has been found for Genentech.

No alerts have been found for Genentech.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 3044 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Chowdhury NN, et al. (2024) Plasminogen deficiency suppresses pancreatic ductal adenocarcinoma disease progression. Molecular oncology, 18(1), 113.

Ma C, et al. (2024) Gasdermin D in macrophages drives orchitis by regulating inflammation and antigen presentation processes. EMBO molecular medicine, 16(2), 361.

Guillen-Guio B, et al. (2024) Association study of human leukocyte antigen variants and idiopathic pulmonary fibrosis. ERJ open research, 10(1).

Lewis GD, et al. (2024) The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nature communications, 15(1), 466.

Lee S, et al. (2024) Deciphering the differential impact of thrombopoietin/MPL signaling on hematopoietic stem/progenitor cell function in bone marrow and spleen. Stem cell reports, 19(2), 211.

House RRJ, et al. (2024) NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. Molecular metabolism, 80, 101876.

Gracia-Hernandez M, et al. (2024) Targeting HDAC6 improves anti-CD47 immunotherapy. Journal of experimental & clinical cancer research : CR, 43(1), 60.

Achanta S, et al. (2024) Pharmacologic Inhibition of Transient Receptor Potential Ion Channel Ankyrin 1 Counteracts 2-Chlorobenzalmalononitrile Tear Gas Agent-Induced Cutaneous Injuries. The Journal of pharmacology and experimental therapeutics, 388(2), 613.

Liu SJ, et al. (2024) Epigenetic reprogramming shapes the cellular landscape of schwannoma. Nature communications, 15(1), 476.

Christensen CF, et al. (2024) Drosophila activins adapt gut size to food intake and promote regenerative growth. Nature communications, 15(1), 273.

Byrnes AE, et al. (2024) A fluorescent splice-switching mouse model enables high-

throughput, sensitive quantification of antisense oligonucleotide delivery and activity. Cell reports methods, 4(1), 100673.

Shojaie L, et al. (2024) Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors. Cell death & disease, 15(2), 140.

Taylor BC, et al. (2024) NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer. Cancer discovery, 14(2), 290.

Lowater SJ, et al. (2024) Clinical Trials and Future Outlooks of the Port Delivery System with Ranibizumab: A Narrative Review. Ophthalmology and therapy, 13(1), 51.

Newton K, et al. (2024) Caspase cleavage of RIPK3 after Asp333 is dispensable for mouse embryogenesis. Cell death and differentiation, 31(2), 254.

Armani-Tourret M, et al. (2024) Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-?2a. Cell, 187(5), 1238.

Seoane R, et al. (2024) SUMOylation modulates eIF5A activities in both yeast and pancreatic ductal adenocarcinoma cells. Cellular & molecular biology letters, 29(1), 15.

Weinelt N, et al. (2024) LUBAC-mediated M1 Ub regulates necroptosis by segregating the cellular distribution of active MLKL. Cell death & disease, 15(1), 77.

Dai J, et al. (2024) Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG1 antibody. mAbs, 16(1), 2304282.

Pedersen KK, et al. (2024) Ablative fractional laser treatment reduces hedgehog pathway gene expression in murine basal cell carcinomas. Lasers in medical science, 39(1), 55.